Life expectancy after an amyloidosis diagnosis ranges from months to decades, depending heavily on which type of amyloidosis you have, which organs are affected, and how quickly effective treatment begins. In immunoglobulin light chain (AL) amyloidosis, roughly a quarter of patients die within six months of diagnosis, while in transthyretin (ATTR) amyloidosis, that same quarter threshold extends to about 24 months.1JAMA. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review Those numbers capture the worst end of a wide spectrum. Many patients, particularly those diagnosed at earlier stages or who respond well to newer therapies, live years or even decades beyond diagnosis.
Why the Type of Amyloidosis Changes Everything
Amyloidosis is not one disease. It is a family of conditions that share a common feature: misfolded proteins depositing in organs and disrupting their function. The three most common systemic forms each have distinct causes, different target organs, and very different timelines.
AL amyloidosis is driven by abnormal plasma cells in the bone marrow that produce misfolded light chain proteins. It tends to affect the heart, kidneys, liver, and nervous system, and it can progress rapidly. A study tracking 194 newly diagnosed AL patients found that median overall survival ranged from over nine years for those caught at the earliest stage down to roughly six months for those diagnosed at the most advanced stage.2PubMed Central. A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis That tenfold gap between early and late stage underscores how much timing matters.
ATTR amyloidosis comes in two forms. Wild-type ATTR (ATTRwt), sometimes called senile cardiac amyloidosis, typically appears in men over 70 and involves the heart. Hereditary ATTR (ATTRv) is caused by a genetic mutation in the transthyretin gene, tends to appear earlier in life, and can affect the nerves, heart, or both. In a study from Crete, hereditary carriers were diagnosed nearly two decades younger on average than wild-type patients and initially had better heart function and quality of life.3PubMed. Cardiac remodeling and arterial stiffness progression in wild-type vs hereditary transthyretin amyloidosis in Crete Both forms of ATTR generally progress more slowly than AL, but cardiac involvement can still shorten life considerably.
AA amyloidosis arises from chronic inflammation, often in the setting of conditions like rheumatoid arthritis or chronic infections. The main target organ is the kidney. In a landmark natural history study, patients whose underlying inflammation was well controlled — keeping a key blood marker below 10 mg per liter — saw amyloid deposits actually shrink in about 60% of cases, and their survival was significantly better than those whose deposits continued to grow.4PubMed. Natural history and outcome in systemic AA amyloidosis For AA patients, long-term outlook is closely tied to how effectively the underlying inflammatory disease can be controlled.
Cardiac Involvement Is the Single Biggest Threat
Across all types of amyloidosis, the heart is the organ that matters most for survival. When amyloid protein infiltrates the heart muscle, it stiffens the walls, impairs the heart’s ability to fill and pump, and can trigger dangerous rhythm problems. Cardiac amyloid infiltration is the leading predictor of death.5PubMed Central. AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects
This is true in AL amyloidosis, where heart involvement drives the staging system that most directly predicts survival. It is equally true in ATTR amyloidosis, where cardiac disease is nearly universal. The staging system developed at the UK National Amyloidosis Centre for ATTR cardiac amyloidosis uses just two widely available blood tests — a marker of heart strain and a measure of kidney function — to sort patients into three stages with meaningfully different survival curves.6PubMed. A new staging system for cardiac transthyretin amyloidosis Patients in the earliest stage can live many years; those in the most advanced stage have a much shorter timeline.
In AL amyloidosis specifically, longer delay between the onset of heart failure symptoms and diagnosis correlates with worse cardiac staging at the time of diagnosis.7PubMed. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement The heart does not wait patiently while the diagnosis is worked out. Every month of untreated amyloid deposition chips away at the heart’s reserve.
Diagnostic Delay Directly Shortens Survival
Amyloidosis is notoriously difficult to diagnose. Symptoms like fatigue, shortness of breath, swollen ankles, and numbness in the hands and feet overlap with dozens of more common conditions, and many patients see multiple specialists before anyone considers amyloidosis. That delay is not just frustrating — it is dangerous.
In ATTR cardiac amyloidosis, a study tracking outcomes after the onset of red-flag symptoms found that each additional unit of time between recognizable warning signs and actual diagnosis independently increased the risk of death. The hazard was even steeper for cardiovascular-specific death.8PubMed. Clinical Impact of Diagnostic Delay by Red Flags Assessment in Transthyretin Amyloid Cardiomyopathy This makes practical sense: treatment cannot begin until the diagnosis is made, and the disease continues to advance unchecked during the delay.
The takeaway for patients and their families is blunt. If you have unexplained heart failure, especially with a thickened heart wall on imaging, or neuropathy with no clear cause, or protein spilling into your urine for no obvious reason, ask about amyloidosis. Getting the right diagnosis sooner is one of the most consequential things you can do for your survival.
How Treatment Has Reshaped AL Amyloidosis Survival
AL amyloidosis treatment targets the rogue plasma cells that produce the toxic light chain proteins. The goal is to eliminate those cells as quickly and completely as possible, halting the production of new amyloid. Treatment response, measured in the blood within weeks, has a dramatic effect on how long patients live.
In patients with advanced cardiac AL amyloidosis, achieving a hematologic response within one month of starting treatment was associated with a median survival of 30 months, compared to just five months in those who did not respond.9PubMed Central. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis Deeper responses translated to even better outcomes: patients who achieved a very good response by one month had a median survival of nearly four years. This paints a picture where the speed and depth of response to initial therapy is one of the strongest predictors of outcome, sometimes mattering as much as the stage at diagnosis.
The addition of daratumumab, an antibody therapy originally developed for myeloma, to a standard three-drug backbone has become the new frontline standard. In the pivotal ANDROMEDA trial, patients who received daratumumab plus the standard regimen had far higher rates of complete hematologic response — over half achieved a complete response, compared to roughly one in five on the standard regimen alone. The daratumumab group also experienced fewer episodes of organ deterioration and better overall survival.10PubMed. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Longer-term follow-up confirmed that adding daratumumab reduced early deaths and prolonged both event-free and overall survival.11PubMed Central. Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis
For eligible patients, autologous stem cell transplant remains a powerful option. Long-term data show that about 30% of AL patients who underwent transplant between 1996 and 2003 were alive 15 years later, despite a period when transplant-related mortality was higher than it is today.12PubMed. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis Not everyone is a candidate — your heart and other organs need to be strong enough to tolerate the procedure — but for those who qualify and respond well, the long-term outlook can be genuinely good.
Treatments Changing the ATTR Outlook
ATTR amyloidosis treatment has undergone a transformation in recent years. Tafamidis, a drug that stabilizes the transthyretin protein and prevents it from misfolding, was the first therapy to show a survival benefit in ATTR cardiac amyloidosis. In the landmark ATTR-ACT trial, tafamidis reduced all-cause mortality compared to placebo, with about 30% of treated patients dying over 30 months versus roughly 43% on placebo.13PubMed. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy Patients on tafamidis also had fewer hospitalizations for heart problems.
Long-term extension data made the case even stronger. After nearly five years of follow-up, patients who had been on tafamidis from the start had significantly better survival than those who started on placebo and switched to tafamidis later. About 45% of continuous tafamidis patients had died by that point, compared to nearly 63% in the delayed-start group.14PubMed Central. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy The gap between those who started treatment earlier and those who started later reinforces the message about diagnostic delay — earlier treatment protects heart function in a way that cannot be fully recaptured by starting later.
For hereditary ATTR with polyneuropathy, gene-silencing therapies — drugs that reduce the liver’s production of transthyretin protein — have shown meaningful benefits in slowing nerve damage and preserving quality of life. Delayed treatment with these agents negatively affects survival, adding yet another incentive for prompt diagnosis.15Blood. Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments Gene-editing approaches using CRISPR technology are also in development, potentially offering a one-time treatment to permanently reduce transthyretin production.
When the Kidneys Bear the Burden
Kidney involvement is extremely common in AL amyloidosis, present in roughly 70% of patients at the time of diagnosis.16PubMed. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor The kidneys leak protein into the urine, gradually losing function as amyloid deposits accumulate. The speed and completeness of clearing the abnormal light chains from the bloodstream directly determines whether kidney function can be preserved or even improved.
In AA amyloidosis, the kidneys are the primary target organ. A study of 121 patients with kidney-involved AA amyloidosis found that over half required dialysis during the follow-up period, with average kidney survival of about five years. Patients who started out with worse kidney function, lower blood protein levels, or who needed dialysis early had particularly poor outcomes.17PubMed Central. Outcome of 121 patients with renal amyloid a amyloidosis For both types, preserving kidney function is a race against ongoing amyloid deposition, and winning that race depends on controlling the source of the amyloid protein as quickly as possible.
Organ Transplantation as a Lifeline
For patients whose heart or kidneys have been severely damaged by amyloid deposits, organ transplantation can be a viable option, though it requires careful patient selection. Heart transplantation in amyloidosis patients has historically been viewed cautiously — if the underlying disease is not controlled, amyloid will simply re-deposit in the new organ. But in selected patients, outcomes have been reasonable.18PubMed. Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience
The strategy has evolved. In AL amyloidosis, heart transplant is sometimes performed to stabilize the patient, followed by stem cell transplant to eliminate the underlying plasma cell disorder. Some centers have reported performing combined heart-kidney or heart-liver transplants depending on which organs are most affected.19JHLT Open. Outcomes of Orthotopic Heart Transplantation in Patients With Light Chain Amyloidosis: A Contemporary Single-Center Experience For ATTR amyloidosis, the availability of effective disease-modifying therapies like tafamidis means that post-transplant amyloid recurrence is less of a concern, broadening the pool of potential candidates. Liver transplant was historically the main treatment for hereditary ATTR, since the liver produces most of the body’s transthyretin, though gene-silencing drugs have largely replaced this approach.
Emerging Therapies Aimed at Clearing Existing Deposits
Current treatments for amyloidosis mostly work by stopping the production of new amyloid protein. They do not directly remove amyloid that has already been deposited in organs. This is a critical unmet need: even after the source of amyloid is shut off, existing deposits can continue to impair organ function.
A new class of therapies aims to change this. Birtamimab is an antibody designed to bind to misfolded light chains and promote the body’s immune cells to clear amyloid deposits from organs.20PubMed Central. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial Another antibody, CAEL-101, targets amyloid fibrils directly and is being tested in two large phase 3 trials focused on patients with the most advanced cardiac AL amyloidosis.21Journal of Clinical Oncology. Enrolling patients in Cardiac Amyloid Reaching for Extended Survival (CARES) trials If these drugs prove effective, they could meaningfully extend survival in advanced patients by actually reversing organ damage rather than merely preventing further deposition.
Racial and Socioeconomic Disparities
Not everyone faces the same odds after an amyloidosis diagnosis. A genetic variant called Val122Ile, carried by roughly 3-4% of Black Americans, causes a hereditary form of ATTR cardiac amyloidosis that tends to carry a worse prognosis than wild-type ATTR. In a study examining racial differences in ATTR cardiac amyloidosis outcomes, Black patients were over 2.5 times more likely to be hospitalized for heart failure or die over five years compared to White patients, even after adjusting for disease stage at diagnosis.22JACC: CardioOncology. Race and Socioeconomic Status Impact Diagnosis and Clinical Outcomes in Transthyretin Cardiac Amyloidosis
The disparity was not purely genetic. Black patients in the study were far more likely to live in the most socioeconomically deprived areas, which likely contributed to delayed diagnosis, reduced access to specialized care, and worse outcomes. This is a sobering reminder that survival statistics reflect not just biology and treatment, but also the inequities baked into healthcare access.
Living with Amyloidosis Beyond the Numbers
Survival statistics capture one dimension of life after diagnosis, but amyloidosis also takes a substantial toll on daily functioning and mental health. Autonomic nerve damage — where the nerves controlling involuntary body functions are affected — is a particularly underappreciated problem. In one study of amyloidosis patients with neuropathy, roughly three-quarters experienced lightheadedness or fainting upon standing, about 70% had gastrointestinal problems like early fullness, nausea, or diarrhea, and over half had disrupted sweating patterns.23PubMed Central. Patterns of Neuropathy and Autonomic Failure in Patients With Amyloidosis Autonomic dysfunction in hereditary ATTR often appears early and has a substantial impact on disease severity, survival, and quality of life.24NeurologÃa. Evaluation of autonomic dysfunction in hereditary transthyretin amyloidosis
The psychological weight is equally heavy. A systematic review of anxiety and depression in cardiac amyloidosis found strikingly high rates. Among patients with AL cardiac amyloidosis, some studies reported that nearly every participant screened positive for clinical depression, while anxiety rates ranged from about 47% to 100%. Patients with ATTR cardiac amyloidosis fared somewhat better but still carried a heavy burden, with depression found in roughly 10-49% and anxiety in about 28-33%.25PubMed Central. Anxiety and depression in cardiac amyloidosis: a systematic review These numbers vary widely across studies partly because of differences in how depression and anxiety were measured, but the overall picture is clear: mental health is a major part of the disease burden and deserves active attention from care teams.
Managing symptoms like fluid retention, fatigue, nerve pain, and gastrointestinal problems meaningfully affects quality of life even when they do not directly change the survival numbers. Patients who are connected to an amyloidosis center with a multidisciplinary team — cardiologists, hematologists, nephrologists, neurologists, and palliative care specialists working together — tend to have smoother symptom management and better coordination of care. If you or someone you know has been diagnosed, finding such a center is worth the effort, even if it means traveling.
How Treatment Response Tracking Works
One of the more hopeful aspects of modern amyloidosis care is that doctors can get early signals about whether treatment is working. In AL amyloidosis, blood tests measuring the abnormal light chain proteins can reveal whether production is dropping within weeks of starting therapy. As described earlier, one-month response is strongly predictive of long-term survival. But the picture is richer than a single blood test.
Researchers have developed composite response models that combine hematologic response with organ response — meaning not just whether the toxic protein is declining, but whether the damaged organs are actually recovering function.26Blood Cancer Journal. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis Patients who achieve both types of response early in treatment have the best outcomes. This dual tracking gives patients and doctors something actionable: if the initial regimen is not producing a deep response quickly, there is a strong case for switching to a more aggressive approach without waiting months to see if things improve on their own.
In ATTR amyloidosis, response tracking is less straightforward because the disease progresses more slowly and the biomarkers change more gradually. Doctors monitor heart strain markers, echocardiographic findings, and functional measures like six-minute walk distance over time. Stable or improving values on tafamidis or gene-silencing therapy are taken as evidence that the disease is being controlled, even if dramatic reversal is uncommon.